TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James “Jay” Richardson, whose leadership helped shape NurExone during its formative years.
“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed deeply in our technology, our team, and the opportunity we are working to build. May his memory be for a blessing,” said Yoram Drucker, Chairman of the Board of NurExone. “We also welcome David to the Board. He understands what it takes to move from innovative technology to disciplined execution, and we believe his perspective will be an important addition as NurExone continues to grow.”